Aarti Drugs Targets 15-16% EBITDA Margin On Higher Sayakha Utilisation, Metformin Volumes: CFO

Aarti Drugs' CFO has set a clear target to improve the company's profitability by achieving an EBITDA margin between 15-16%. This goal is primarily driven by the increased utilisation of its Sayakha manufacturing facility, which is expected to boost production efficiency and lower costs. The management also expects steady growth in Metformin volumes, a key generic drug, to support these margins.

For investors, this update signals a strategic push to enhance operational efficiency and maintain a competitive edge in the generic space. The focus on regulated markets like Western Europe and the US indicates a broader ambition to diversify revenue streams beyond domestic markets. This move could be crucial for long-term growth, especially as the company seeks to stabilise its margins in a fluctuating market environment.

Moving forward, investors should monitor the company's progress on Sayakha utilisation rates and its ability to secure a stronger foothold in regulated markets. Any delays or challenges in these areas could impact the achievement of the margin targets. Keeping an eye on regulatory approvals and demand trends in key markets will be essential to gauge the success of this strategy.